Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) EBITDA (2023 - 2025)

Mereo BioPharma (MREO) has disclosed EBITDA for 3 consecutive years, with -$9.3 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 18.73% to -$9.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$41.4 million, a 18.8% decrease, with the full-year FY2024 number at -$44.6 million, down 76.6% from a year prior.
  • EBITDA was -$9.3 million for Q3 2025 at Mereo BioPharma, down from -$8.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$351000.0 in Q2 2023 to a low of -$14.8 million in Q4 2024.
  • A 3-year average of -$8.8 million and a median of -$9.3 million in 2025 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 3390.03% in 2024, then skyrocketed 34.95% in 2025.
  • Mereo BioPharma's EBITDA stood at -$5.0 million in 2023, then plummeted by 195.47% to -$14.8 million in 2024, then surged by 37.18% to -$9.3 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's EBITDA are -$9.3 million (Q3 2025), -$8.0 million (Q2 2025), and -$9.3 million (Q1 2025).